Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04373902
Other study ID # PinC trial
Secondary ID NL7853
Status Recruiting
Phase N/A
First received
Last updated
Start date May 11, 2020
Est. completion date July 1, 2024

Study information

Verified date September 2023
Source Erasmus Medical Center
Contact Philip LJ DeKoninck, Dr.
Phone 0031107036614
Email p.dekoninck@erasmusmc.nl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Pulmonary hypertension is a major determinant of postnatal survival in infants with a congenital diaphragmatic hernia (CDH). The current care during the perinatal stabilisation period in infants born with this rare birth defect might contribute to the development of pulmonary hypertension after birth - in particular umbilical cord clamping before lung aeration. An ovine model of diaphragmatic hernia demonstrated that cord clamping after lung aeration, called physiological-based cord clamping (PBCC), avoided the initial high pressures in the lung vasculature while maintaining adequate blood flow, thereby avoiding vascular remodelling and aggravation of pulmonary hypertension. The investigators aim to investigate if the implementation of PBCC in the perinatal stabilisation period of infants born with a CDH could reduce the incidence of pulmonary hypertension in the first 24 hours after birth. The investigators will perform a multicentre, randomised controlled trial in infants with an isolated CDH. Before birth, infants will be randomised to either PBCC or immediate cord clamping, stratified by treatment centre and severity of pulmonary hypoplasia on antenatal ultrasound. For performing PBCC a purpose-designed resuscitation module (the Concord Birth Trolley) will be used.


Recruitment information / eligibility

Status Recruiting
Enrollment 140
Est. completion date July 1, 2024
Est. primary completion date June 1, 2024
Accepts healthy volunteers No
Gender All
Age group 35 Weeks and older
Eligibility Inclusion Criteria: - Left-sided CDH - Isolated CDH: no associated structural or genetic abnormalities that are diagnosed before birth - Gestational age at delivery =35.0 weeks - Parental written informed consent Exclusion Criteria: - Right-sided or bilateral CDH - Gestational age at delivery <35.0 weeks - Maternal contraindications: anterior placenta praevia, placental abruption - High urgency caesarean section, with intended interval to delivery <15 min - Cases that have been treated during pregnancy with experimental drug therapy aiming to decrease the occurrence of pulmonary hypertension - Twin pregnancies in which the infant diagnosed with a CDH is born first - Multiple birth >2 (triplets or higher order)

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Physiological-based cord clamping
See 'Arm'

Locations

Country Name City State
Australia Monash University Melbourne
Austria Medical University Graz Graz
Belgium University Hospitals leuven Leuven
Germany Universitätskrankenhaus Bonn Bonn
Germany Universitätsklinik Mannheim Mannheim
Italy Ospedale Pediatrico Bambino Gesu Rome
Netherlands Radboudumc University Medical Center Nijmegen
Netherlands Erasmus MC University Medical Center - Sophia Children's Hospital Rotterdam
Sweden Karolinska University Hospital Stockholm

Sponsors (1)

Lead Sponsor Collaborator
Erasmus Medical Center

Countries where clinical trial is conducted

Australia,  Austria,  Belgium,  Germany,  Italy,  Netherlands,  Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants with pulmonary hypertension diagnosed in the first 24 hours after birth. Pulmonary hypertension is present if at least 2 of the following 4 criteria are present or if the infant requires extracorporeal membrane oxygenation (ECMO) in the first 24 hours after birth:
Right ventricular systolic pressure (RVSP) =2/3 systemic systolic pressure*
Right ventricle (RV) dilatation/septal displacement or RV dysfunction +/- left ventricle (LV) dysfunction*
Pre-post ductal SpO2 difference >10% for at least 15 consecutive minutes
Oxygenation Index >20** *as found on first ultrasound in first 24 hours after birth; **highest value measured in first 24 hours after birth
The following echocardiographic parameters will be collected to objectify these criteria:
RV size
Pulmonary artery acceleration time (PAAT), right ventricular ejection time (RVET), PAAT:RVET ratio
Intraventricular septum configuration
LV systolic eccentricity index
Mean airway pressure
PaO2
FiO2
Preductal+postductal SpO2
First 24 hours after birth
Secondary Neonatal: mortality before discharge from the tertiary care hospital Number of patients that died before discharge From birth till discharge from the tertiary care hospital, through study completion an average of one year
Secondary Neonatal: presence of 3 or more criteria for pulmonary hypertension or extracorporeal membrane oxygenation within 24 hours after birth Number of patients with 3 or more criteria or ECMO The first 24 hours after delivery
Secondary Neonatal: number of patients requiring ECMO therapy Number of patients requiring ECMO therapy From admission to the ICU until the date of death or the date of discharge home, whichever came first
Secondary Neonatal: number of days of duration of supplemental oxygen need Number of days of duration of supplemental oxygen need From admission to the ICU until the date of discharge to another ward or home, whichever came first,through study completion an average of one year
Secondary Neonatal: number of days of duration of mechanical ventilation Number of days of duration of mechanical ventilation From admission to the ICU until the date of discharge to another ward or home, whichever came first,through study completion an average of one year
Secondary Neonatal: duration of admission to the tertiary care hospital Number of days of admission to the tertiary care hospital From admission to the ICU until the date of discharge to another ward or home, whichever came first
Secondary Maternal: number of patients with postpartum haemorrhage Postpartum haemorrhage is defined as estimated blood loss >1000 mL The first 24 hours after delivery
See also
  Status Clinical Trial Phase
Withdrawn NCT01950585 - Hydroxyurea in Pulmonary Arterial Hypertension Early Phase 1
Completed NCT00527163 - Role of Nitric Oxide in Malaria
Completed NCT03649932 - Enteral L Citrulline Supplementation in Preterm Infants - Safety, Efficacy and Dosing Phase 1
Recruiting NCT04554160 - Arrhythmias in Pulmonary Hypertension Assessed by Continuous Long-term Cardiac Monitoring
Enrolling by invitation NCT03683186 - A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension Phase 3
Completed NCT01894035 - Non-interventional Multi-center Study on Patients Under Routine Treatment of Pulmonary Arterial Hypertension (PAH) With Inhaled Iloprost Using I-Neb as a Device for Inhalation
Not yet recruiting NCT04083729 - Persistent Pulmonary Hypertension After Percutaneous Mitral Commissurotomy N/A
Completed NCT02821156 - Study on the Use of Inhaled NO (iNO) N/A
Completed NCT02216279 - Phase-II Study of the Use of PulmoBind for Molecular Imaging of Pulmonary Hypertension Phase 2
Terminated NCT02246348 - Evaluating Lung Doppler Signals in Patients With Systemic Sclerosis (SSc) N/A
Terminated NCT02243111 - Detecting Pulmonary Arterial Hypertension (PAH) in Patients With Systemic Sclerosis (SSc) by Ultrasound N/A
Recruiting NCT01913847 - Safety and Efficacy Study of HGP1207 in Patients With Pulmonary Hypertension Phase 3
Completed NCT01615484 - Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability N/A
Completed NCT06240871 - Contrast Enhanced PA Pressure Measurements
Completed NCT02377934 - Evaluation of Radiation Induced Pulmonary Hypertension Using MRI in Stage III NSCLC Patients Treated With Chemoradiotherapy. A Pilot Study
Recruiting NCT01091012 - Effectiveness of the Vasodilator Test With Revatio, Made in Patients With Acute Pulmonary Hypertension Phase 3
Completed NCT01463514 - Noninvasive Determination of Cerebral Tissue Oxygenation in Pulmonary Hypertension N/A
Completed NCT02275793 - The Regulation of Pulmonary Vascular Resistance in Patients With Heart Failure
Completed NCT00739375 - The Effect of Blood Flow in the Maturing Arteriovenous Access for Hemodialysis on the Development of Pulmonary Hypertension. Phase 1
Completed NCT01484899 - Smoking: a Risk Factor for Pulmonary Arterial Hypertension? N/A